AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones. The therapy is undergoing clinical development for patients suffering from...

Kite, a Gilead Company ,  announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell...

Sun Pharmaceutical Industries Limited had announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1...

Torrent Pharmaceuticals, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR at an equity valuation of Rs256.89bn ($3bn) on a fully diluted basis. The move is part of...

Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made by the subsidiary of Merck, which is known as MSD outside of the US and Canada. The deal values London-based Verona at about $107 per American depository share,...

Sanofi announced the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and...

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities. The strategic transaction will combine complementary mRNA...

Eli Lilly and Company and SiteOne Therapeutics, , a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne “The global...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Although Vigil has two candidates in...

Novo Holdings, a global investment firm focused on life sciences, has completed its previously announced acquisition of Catalent. Under private ownership, Catalent benefits from Novo Holdings’ significant resources, and is well-positioned to deliver unparalleled outcomes for...